Novel management of pseudomonas biofilm-like structure in a post-pneumonectomy empyema

Front Cell Infect Microbiol. 2024 Oct 17:14:1458652. doi: 10.3389/fcimb.2024.1458652. eCollection 2024.

Abstract

We present a patient with a post-pneumonectomy empyema refractory to surgical debridement and systemic antibiotics. The patient initially presented with a bronchopleural fistula and pneumothorax secondary to tuberculosis (TB) destroyed lung, which required a pneumonectomy with Eloesser flap. Ongoing pleural infection delayed the closure of the Eloesser flap, and thoracoscopic inspection of his chest cavity revealed a green, mucous biofilm-like structure lining the postpneumonectomy pleural cavity. Cultures identified pan-susceptible Pseudomonas aeruginosa. Despite debriding this biofilm-like structure and administering systemic antibiotics, the patient continued to show persistent signs of infection and regrowth of the film. We employed a novel approach to dissolve the biofilm-like structure using intrapleural dornase alfa followed by intrapleural antibiotic washes. After 3 weeks of daily washes, repeat inspection demonstrated the biofilm-like structure had completely resolved. Resolving the pseudomonas biofilm-like structure allowed permanent closure of his chest without further need for systemic antibiotics. At follow up 3 months later, he showed no sequalae. This treatment option can be an important adjunct to improve likelihood of chest closure in patients with post-pneumonectomy empyema that resists standard treatment options due to biofilm formation.

Keywords: alfa; biofilm-like structure; dornase; empyema; pneumonectomy; pseudomonas; tuberculosis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Biofilms* / drug effects
  • Biofilms* / growth & development
  • Debridement
  • Empyema, Pleural / drug therapy
  • Empyema, Pleural / etiology
  • Empyema, Pleural / microbiology
  • Empyema, Pleural / surgery
  • Humans
  • Male
  • Middle Aged
  • Pneumonectomy*
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas Infections* / microbiology
  • Pseudomonas aeruginosa* / drug effects
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported fully or in part by the Intramural Research Program of the National Institutes of Health, NHLBI, and NCI (AG, RR, IA, KPF, and SC). Funding is also from MRC (UK) Grant: MC_UU_00031/7 (KMF).